Is Nurix Therapeutics (NRIX) stock Halal?

Nurix Therapeutics is a biotechnology firm focused on developing therapies to address immune system disorders and cancers. At the heart of its innovative approach is the modulation of protein levels within cells, a critical factor in disease progression. Nurix employs its proprietary DELigase platform to discover and design targeted therapies that either enhance or degrade specific proteins through ubiquitin proteasome system engagement. Before any of that matters to a Muslim investor, one question comes first: is Nurix Therapeutics stock Halal?

Is Nurix Therapeutics Shariah compliant?

No. In the October 2026 screening Nurix Therapeutics (NRIX) does not pass AAOIFI screening: it fails the non-permissible income screen. The Shariah case on a technology company like Nurix Therapeutics is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does Nurix Therapeutics pass the business activity test?

The activity screen is only part of the picture this month: Nurix Therapeutics currently fails the non-permissible income screen, so the overall verdict is not compliant regardless of the business itself. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Nurix Therapeutics' income Halal?

No. Nurix Therapeutics' income from impermissible sources currently exceeds AAOIFI's 5% revenue ceiling, which makes the stock non-compliant on this screen regardless of the others. The screen is reassessed monthly, so the status can change when new financial statements arrive.

Does Nurix Therapeutics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation, measured against a market capitalisation of $2.46B (market data as of 1 October 2026). Because the caps move with the share price, our Shariah Supervisory Board has NRIX re-screened every month, and the result above always shows the latest verdict.

Why do other halal screeners show a different verdict for Nurix Therapeutics?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read Why a Halal Stock Screener Matters for Halal Investing